Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strides Pharma Science Limited

http://www.strides.com/

Latest From Strides Pharma Science Limited

Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Sales & Earnings Biosimilars

Strides Sees COVID-19 Pills Not Impacting Vaccine Uptake

Strides’ CEO tells Scrip Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4. Meanwhile, US revenue guidance of $225-250m has been pushed back by a year to FY23.

Coronavirus COVID-19 Business Strategies

Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit

Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock.

Leadership Sales & Earnings

Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit

Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock

Commercial Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Strides Arcolab Ltd.
    • Strides Arcolab Limited
    • Amneal Pharmaceuticals Pty Limited, Australia
    • Faglis Medica Private Limited
    • Strides Shasun Limited
UsernamePublicRestriction

Register